Will O'Bryan

William O’Bryan serves as a key procurement professional within the CDC Office of Acquisition Services, supporting the agency’s mission to safeguard public health through strategic acquisition of scientific, diagnostic, and biomedical resources. He manages complex contracting actions for laboratory equipment, pharmaceuticals, software solutions, and clinical diagnostics, ensuring alignment with federal acquisition regulations and CDC’s operational priorities in infectious disease surveillance and laboratory capacity building. His work directly enables rapid response capabilities and data-driven public health initiatives by securing mission-critical technologies and services from qualified vendors. O’Bryan maintains established relationships with leading contractors including General Dynamics Information Technology, GlaxoSmithKline, Cepheid, MRIGLOBAL, and the New York City Health & Hospitals Corp. These partnerships reflect a focus on high-performance, scalable solutions in diagnostics, biomanufacturing, and health informatics. His contracting approach emphasizes technical rigor, compliance with biosafety standards, and long-term vendor reliability, often resulting in multi-year, performance-based agreements that support sustained public health infrastructure. While the majority of his acquisitions—83.3%—are conducted without set-asides, he consistently prioritizes small business participation, with 13.3% of awards designated as total small business set-asides under FAR 19.5 and an additional 3.3% allocated to women-owned small businesses. This reflects a balanced commitment to competition and socioeconomic goals, aligning with HHS and federal objectives to broaden supplier diversity without compromising mission readiness. His procurement focus centers on NAICS 334516 (analytical laboratory instrumentation), 513210 (software publishers for health analytics), and 325414 (biological product manufacturing), underscoring deep expertise in diagnostic systems, laboratory automation, and biopharmaceutical supply chains. He routinely sources next-generation sequencing platforms, real-time PCR systems, epidemiological data tools, and clinical lab services critical to CDC’s national health surveillance infrastructure.